-
Human medicines European public assessment report (EPAR): Abraxane, paclitaxel, Date of authorisation: 11/01/2008, Revision: 31, Status: Authorised
30 Jan 2025 17:24 GMT
… more effective than conventional paclitaxel-containing medicines. Overall, … the women receiving conventional paclitaxel-containing medicines (37 … effective than conventional paclitaxel-containing medicines in … In non-small cell lung cancer, 33% of patients …
-
Summary of opinion: Imfinzi, 30/01/2025 Positive
31 Jan 2025 16:08 GMT
… unresectable non-small cell lung cancer (NSCLC) in adults whose … positive mutations.
Small Cell Lung Cancer (SCLC)
Imfinzi as … extensive-stage small cell lung cancer (ES SCLC).
Biliary … combination with carboplatin and paclitaxel is indicated for the …
-
Immutep Quarterly Activities Report Q2 FY25
31 Jan 2025 13:00 GMT
… first-line non-small cell lung cancer (1L NSCLC) received first … line metastatic non-small cell lung cancer (1L NSCLC). The receipt … efti in combination with paclitaxel to determine the optimal … non-squamous non-small cell lung cancer (1L NSCLC). Mature data …
-
A Phase 1 Trial of Iadademstat Plus Vidaza Has Dosed a Patient With MDS
30 Jan 2025 00:51 GMT
… solid tumors, including small cell lung cancer, neuroendocrine tumors and medulloblastoma. Ongoing … investigating iadademstat in combination with paclitaxel for refractory or relapsed neuroendocrine …
-
Pancreatic cancer: Oncolytics Biotech, Candel, and CytomX bring promising therapies to the clinic
29 Jan 2025 16:39 GMT
… will be second only to lung cancer in its lethality by 2025 … chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced …
-
High-dose IV vitamin C doubles pancreatic cancer survival
29 Jan 2025 14:43 GMT
… -of-care gemcitabine and nab-paclitaxel alone or with IV vitamin … common with gemcitabine and nab-paclitaxel treatment. The vitamin C cohort … vitamin C in patients with lung cancer.
Other researchers have investigated it …
-
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
29 Jan 2025 12:00 GMT
… . In July 2024, Teva launched paclitaxel protein-bound particles for injectable … or metastatic non-small cell lung cancer, and the treatment of patients …
-
US FDA approves AstraZeneca & Daiichi Sankyo’s Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
29 Jan 2025 04:34 GMT
… choice of chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) in patients with HR … or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating …
-
Daraxonrasib Demonstrates Efficacy, Potential to Inhibit Major RAS(ON) Variants in RAS+ PDAC
28 Jan 2025 17:16 GMT
… -of-care gemcitabine/nab-paclitaxel, modified FOLFIRINOX, NALIRIFOX, or FOLFOX … (PDAC) and non-small cell lung cancer (NSCLC). Ann Oncol. 2023;34 …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
27 Jan 2025 23:07 GMT
… mg/m2 biweekly or paclitaxel (N=7) 80 mg… choice of chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) in patients with HR … or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating …
About
© 1995-2025